i-manager Publications

Dyslipidemia: Diabetes Lipid Therapies

Rehan Haider*, Asghar Mehdi**, Geetha Kumari Das***, Zameer Ahmed Khanzada****, Sambreen Zameer Khanzada*****

* Department of Pharmacy, University of Karachi, Pakistan.

** Department of Pharmacology, Fazaia Ruth Pfau Medical College, Air University, Karachi, Pakistan.

*** OPJS University, Rajasthan, India.

****-***** Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.

Periodicity:January - April'2024
DOI : https://doi.org/10.26634/jls.3.1.20942

Abstract

Dyslipidemia caused by abnormal lipid profiles significantly increases the risk of cardiovascular disease (CVD) in individuals with diabetes. Effective management necessitates a comprehensive approach that encompasses lifestyle modifications and pharmacological intervention. Lifestyle adjustments such as adopting a healthy diet and engaging in regular physical activity play a crucial role in managing dyslipidemia. Avoiding foods high in saturated fat, trans fat, and cholesterol, while incorporating high-fiber foods and omega-3 fatty acids, helps regulate lipid profiles. Regular exercise increases high-density lipoprotein (HDL) cholesterol levels, promotes weight loss, and aids in managing dyslipidemia. While behavioral changes are beneficial, pharmacological treatments are pivotal. Statins are the cornerstone for managing dyslipidemia in diabetic patients, regardless of standard lipid levels, due to their ability to lower low-density lipoprotein (LDL) cholesterol levels. Additional lipid-lowering agents such as ezetimibe, bile acid sequestrants, and PCSK9 inhibitors may complement treatment strategies to improve lipid profiles. The advancements include new formulations of antidiabetic medications that demonstrate favorable effects on lipid parameters in diabetic patients. Sodiumglucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) not only provide cardiovascular benefits but also aid in lowering lipid levels. SGLT-2 inhibitors reduce LDL cholesterol and triglyceride levels, while GLP-1 RAs primarily target triglycerides and LDL cholesterol levels.

Keywords

Dyslipidemia, Diabetes, Lipid-Lowering Therapies, LDL Cholesterol, HDL Cholesterol, LDL Cholesterol-Lowering Agents, Cardiovascular Complications, Blood Glucose Control.

How to Cite this Article?

Haider, R., Mehdi, A., Das, G. K., Khanzada, Z. A., and Khanzada, S. Z. (2024). Dyslipidemia: Diabetes Lipid Therapies. i-manager's Journal on Life Sciences, 3(1), 38-52. https://doi.org/10.26634/jls.3.1.20942

References

[1]. Action to Control Cardiovascular Risk in Diabetes Study Group. (2008). Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine, 358(24), 2545-2559.

[2]. Advance Collaborative Group. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358(24), 2560-2572.

[3]. Assmann, G., Schulte, H., & von Eckardstein, A. (1996). Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. The American Journal of Cardiology, 77(14), 1179- 1184.

[4]. Austin, M. A. (2000). Triglyceride, small, dense low- density lipoprotein, and the atherogenic lipoprotein phenotype. Current Atherosclerosis Reports, 2, 200-207.

[5]. Austin, M. A., McKnight, B., Edwards, K. L., Bradley, C. M., McNeely, M. J., Psaty, B. M., ... & Motulsky, A. G. (2000). Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation, 101(24), 2777-2782.

[6]. Beauchamp, M. C., Michaud, S. É., Li, L., Sartippour, M. R., & Renier, G. (2004). Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression. Journal of Lipid Research, 45(9), 1749-1757.

[7]. Borch-Johnsen, K., Tuomilehto, J., Balkau, B., & Qiao, Q. (1999). Is fasting glucose sufficient to define diabetes? Diabetologia, 1999(42), 647-654.

[8]. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. (2005). JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart, 91(Suppl 5), v1-v52.

[9]. Cefalu, W. T. (2008). Glycemic targets and cardiovascular disease. New England Journal of Medicine, 358(24), 2633-2635.

[10]. Coleman, R., Stevens, R., Retnakaran, R., & Holman, R. (2007). Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care, 30(5), 1292–1293.

[11]. Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., ... & Fuller, J. H. (2004). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. The Lancet, 364(9435), 685-696.

[12]. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications(DCCT/EDIC) Study Research Group. (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine, 353(25), 2643-2653.

[13]. Dluhy, R. G., & McMahon, G. T. (2008). Intensive glycemic control in the ACCORD and ADVANCE trials. The New England Journal of Medicine, 358(24), 2630-2633.

[14]. Durrington, P. N. (2000). Diabetic dyslipidaemia. Baillière's Clinical Endocrinology and Metabolism, 13, 265–278.

[15]. Evans, J. M., Wang, J., & Morris, A. D. (2002). Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ, 324(7343), 939-942.

[16]. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285(19), 2486-2497.

[17]. Goldberg, I. J. (2001). Clinical review 124: Diabetic dyslipidemia: Causes and consequences. The Journal of Clinical Endocrinology and Metabolism, 86(3), 965-971.

[18]. Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., ... & Zamorano, J. L. (2007). Fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (Constituted by representatives of nine societies and by invited experts). European Journal of Cardiovascular Prevention & Rehabilitation, 14(2_suppl), E1-E40.

[19]. Grundy, S. M. (1998). Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. The American Journal of Cardiology, 81(4), 18B-25B.

[20]. Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine, 339(4), 229-234.

[21]. Heart Protection Study Collaborative Group. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360(9326), 7-22.

[22]. Heart Protection Study Collaborative Group. (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. The Lancet, 361(9374), 2005-2016.

[23]. Hokanson, J. E. (1998). Hypertriglyceridemia as a cardiovascular risk factor. The American Journal of Cardiology, 81(4), 7B-12B.

[24]. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359(15), 1577-1589.

[25]. Howard, B. V., Best, L. G., Galloway, J. M., Howard, W. J., Jones, K., Lee, E. T., ... & Devereux, R. B. (2006). Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care, 29(2), 391-397.

[26]. Jensen, T., Borch-Johnsen, K., Kofoed-Enevoldsen, A., & Deckert, T. (1987). Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk factors. Diabetologia, 30, 144-148.

[27]. Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 444(7121), 840-846.

[28]. Kannel, W. B. (1985). Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study. American Heart Journal, 110(5), 1100-1107.

[29]. Kannel, W. B., & McGee, D. L. (1979a). Diabetes and cardiovascular disease: The Framingham study. JAMA, 241(19), 2035-2038.

[30]. Kannel, W. B., & McGee, D. L. (1979b). Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care, 2(2), 120-126.

[31]. Kearney, P. M., Blackwell, L., Collins, R., Keech, A., Simes, J., Peto, R., ... & Baigent, C. (2008). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta- analysis. Lancet, 371(9607), 117-125.

[32]. Knopp, R. H., d'Emden, M., Smilde, J. G., Pocock, S. J., & ASPEN Study Group. (2006). Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care, 29(7), 1478-1485.

[33]. Krolewski, A. S., Kosinski, E. J., Warram, J. H., Leland, O. S., Busick, E. J., Asmal, A. C., ... & Kahn, C. R. (1987). Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. The American Journal of Cardiology, 59(8), 750-755.

[34]. Levitan, E. B., Song, Y., Ford, E. S., & Liu, S. (2004). Is nondiabetic hyperglycemia a r i sk factor for cardiovascular disease? A meta-analysis of prospective studies. Archives of Internal Medicine, 164(19), 2147- 2155.

[35]. Lewis, G. F., Uffelman, K. D., Szeto, L. W., Weller, B., & Steiner, G. (1995). Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. The Journal of Clinical Investigation, 95(1), 158-166.

[36]. Lyons, T. J., & Jenkins, A. J. (1997). Lipoprotein glycation and its metabolic consequences. Current Opinion in Lipidology, 8(3), 174-180.

[37]. Malmberg, K., Yusuf, S., Gerstein, H. C., Brown, J., Zhao, F., Hunt, D., ... & Investigators, F. T. O. R. (2000). Impact of diabetes on long-term prognosis in patients with unstable angina and non–Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation, 102(9), 1014-1019.

[38]. McBride, P. (2008). Triglycerides and risk for coronary artery disease. Current Atherosclerosis Reports, 10(5), 386-390.

[39]. Meigs, J. B., Nathan, D. M., Wilson, P. W., Cupples, L. A., & Singer, D. E. (1998). Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: The Framingham offspring study. Annals of Internal Medicine, 128(7), 524-533.

[40]. Mogensen, C. E. (1984). Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. New England Journal of Medicine, 310(6), 356- 360.

[41]. Otvos, J. D., Collins, D., Freedman, D. S., Shalaurova, I., Schaefer, E. J., McNamara, J. R., ... & Robins, S. J. (2006). Low-density lipoprotein and high- density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation, 113(12), 1556-1563.

[42]. Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & Scandinavian Simvastatin Survival Study (4S) Group. (1997). Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care, 20(4), 614-620.

[43]. Reynolds, T. M., Twomey, P. J., & Wierzbicki, A. S. (2004). Concordance evaluation of coronary risk scores: Implications for cardiovascular risk screening. Current Medical Research and Opinion, 20(6), 811-818.

[44]. Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., ... & Willenheimer, R. (2008). Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. New England Journal of Medicine, 359(13), 1343-1356.

[45]. Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., ... & Furberg, C. D. (2000). Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The prospective pravastatin pooling project. Circulation, 102(16), 1893-1900.

[46]. Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., ... & Gudnason, V. (2007). Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation, 115(4), 450-458.

[47]. Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007). Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiological Reviews, 87(2), 507-520.

[48]. Scandinavian Simvastatin Survival Study Group. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). The Lancet, 344(8934), 1383-1389.

[49]. Scheffer, P. G., Teerlink, T., & Heine, R. J. (2005). Clinical significance of the physicochemical properties of LDL in type 2 diabetes. Diabetologia, 48, 808-816.

[50]. Shafrir, E., & Raz, I. (2003). Diabetes: Mellitus or lipidus? Diabetologia, 46, 433-440.

[51]. Simons, L. A., & Simons, J. (1998). Diabetes and coronary heart disease. The New England Journal of Medicine, 339(23), 1714-1715.